Bardur Sigurgeirsson
Reykjavik, Iceland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Utilizing relative survival to investigate melanoma subtypes across intersectional demographics: a Surveillance, Epidemiology, and End Results (SEER) cohort study.
Journal: Skin health and disease
Published: April 20, 2026
Relative survival analysis of Merkel cell carcinoma across intersectional demographics using the Surveillance, Epidemiology, and End Results (SEER) database.
Journal: JAAD international
Published: December 15, 2025
Relative survival analysis of dermatofibrosarcoma protuberans, Kaposi sarcoma, and pleomorphic sarcoma across intersectional demographics: A Surveillance, Epidemiology, and End Results (SEER) study.
Journal: Journal of the American Academy of Dermatology
Published: October 15, 2025
The incidence and impact of melanoma subtypes in Iceland 1955-2023.
Journal: The British journal of dermatology
Published: May 13, 2025
A partial loss-of-function variant in STAT6 protects against type 2 asthma.
Journal: The Journal of allergy and clinical immunology
Published: February 29, 2024
A genome-wide association meta-analysis links hidradenitis suppurativa to common and rare sequence variants causing disruption of the Notch and Wnt/β-catenin signaling pathways.
Journal: Journal of the American Academy of Dermatology
Published: February 16, 2024
Gene-based burden tests of rare germline variants identify six cancer susceptibility genes.
Journal: Nature genetics
Published: August 15, 2023
Position statement: Recommendations on the diagnosis and treatment of Malassezia folliculitis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 11, 2023
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Journal: The British journal of dermatology
Published: January 05, 2022
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Journal: Dermatologic therapy
Published: October 27, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
Journal: The Journal of dermatological treatment
Published: April 26, 2021
Keratinocytes secrete multiple inflammatory and immune biomarkers, which are regulated by LL-37, in a psoriasis mimicking microenvironment.
Journal: Scandinavian journal of immunology
Published: December 22, 2020
Last Updated: 09/26/2026